Cyclopharm Limited (CYC) Stock Statistics & Valuation Metrics

Cyclopharm Limited has a market cap or net worth of AU$56.58M. The enterprise value is AU$51.92.

Cyclopharm Limited has 125,734,146 shares outstanding. The number of shares has decreased by -2.65% in one year.

Cyclopharm Limited’s return on equity (ROE) is -0.64 and return on invested capital (ROIC) is -49.53%.

The current PE Ratio of Cyclopharm Limited is ―. Cyclopharm Limited’s PEG ratio is -0.27.

In the last 12 months, Cyclopharm Limited had revenue of 32.33M and earned -17.22M in profits. Earnings per share was -0.16.

In the last 12 months, operating cash flow was -17.51M and capital expenditures -1.98M, giving a free cash flow of -19.49M billion.

Cyclopharm Limited pays an annual dividend of AU$0.008, resulting in a dividend yield of 0.64%

Cyclopharm Limited upcoming earnings date is Feb 24, 2027, TBA (Confirmed).

Cyclopharm Limited as a current ratio of 2.53, with Debt / Equity ratio of 24.48%

In the past 12 months, Cyclopharm Limited has paid -636.78K in taxes.

Cyclopharm Limited EV to EBITDA ratio is -7.08, with an EV/FCF ratio of -6.02.

Cyclopharm Limited has AU$12.25M in cash and marketable securities with AU$7.80M in debt, giving a net cash position of AU$4.44M billion.

Gross margin is -1.41%, with operating margin of -56.25%, and net profit margin of -53.27%.

The average price target for Cyclopharm Limited is AU$1.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy